Search

Search Constraints

You searched for: Author/Creator Yu, Rosie Z.

Search Results

1. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides. (26th July 2022)

2. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. (7th December 2020)

3. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. (7th December 2020)

4. Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey. (16th June 2014)

5. Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey. (July 2014)

7. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. (23rd June 2021)

8. Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis. Issue 12 (7th August 2022)